T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop

May-Lucie Meyer

doi:10.1016/j.ctrv.2026.103201

T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop

2026-08-10

0

PRE

AI

M

May-Lucie Meyer

S

Solange Peters

M

Myung-Ju Ahn

I

Isabelle Beuchat

H

Hossein Borghaei

L

Lauren A. Byers

F

Federico Cappuzzo

N

Noura J. Choudhury

J

Johann de Bono

E

Enriqueta Felip

C

Carl M. Gay

R

Ramaswamy Govindan

F

Felix John

S

Stephen V. Liu

M

Margarita Majem

M

Markus G. Manz

A

Arancha Manzano

T

Tony Mok

G

Giannis Mountzios

J

Jarushka Naidoo

DOI：10.1016/j.ctrv.2026.103201

Original

Original request for help

Save

Abstract

En 中文

• Various T-cell engagers (TCEs) are in development for small-cell lung cancer (SCLC). • Tarlatamab is a DLL3-targeted TCE approved for use in pretreated SCLC. • Safe and effective implementation of TCE therapy requires: • Effective TCE-related side-effect management. • Multidisciplinary collaboration and patient/caregiver education.

T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop

Abstract

Journal

Organization

Cited Papers

Citing Papers